

03 - 18 - 02 SN: 10/009,009

JULY Rec'd PCT/PTO 13 MAR 2002

PCT
8

CASE 4-30972A

9/23/02
89



FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV 041586262US
Express Mail Label Number

March 14, 2002
Date of Deposit

RECEIVED

SEP 09 2002

TECH CENTER 1600/29

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

BRAIN ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP00/05059

FILED: 2 JUNE 2000

U.S. APPLICATION NO: 10/009,009

35 USC §371 DATE: 3 DECEMBER 2001

FOR: BRADYKININ RECEPTOR ANTAGONISTS

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:


Applicants believe this paper is being filed before the mailing date of a first Office action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed reference WO 9725315 A was cited in the international stage search report, a copy of which is enclosed herewith. Since the listed reference is of record in the instant PCT application PCT/EP00/05059, a copy is not enclosed. Applicants are enclosing U.S. Patent 6,100,278, which they believe to be substantially equivalent to WO 97/25315A.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,



Carol A. Loeschorn
Attorney for Applicants
Reg. No. 35,590

Novartis Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027
(908) 522-6932

Date: *March 14, 2002*